Read through our coverage of the National Kidney Foundation's 2017 Spring Clinical Meetings.
As 25(OH)D levels increased, systolic blood pressure decreased significantly, even after accounting for calcium intake.
In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.
A patient experienced painful skin ulcers despite having normal renal function.
At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.
In a study, vonapanitase did not improve primary patency compared with placebo, but did improve secondary patency and fistula use for hemodialysis.
Significantly more patients treated with ferric citrate increased their hemoglobin levels by 1 g/dL or more over 8 weeks.
Adult patients with horseshoe kidneys have an estimated kidney stone incidence of 59%.
Among hemodialysis patients, sudden cardiac death accounted for 12% more cardiovascular-related mortalities in 2013 than in 2009.
Study demonstrates decreased risk of end-stage renal disease and all-cause mortality.
The prevalence of low hemoglobin levels increases with declining renal function.
Renal and Urology News Articles
- Keytruda Approved for All Cancers With Specific Genetic Biomarker
- Renal, Bladder Cancer Linked to Physical Inactivity
- Residual Kidney Function Predicts Mortality in CKD-MBD
- Pure Bladder Cancer Variants Linked to Worse Survival After RC
- Combined Urinary Testing Helps Detect Aggressive PCa, Avoid Biopsy
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)